There are very few hematological emergencies that they are usually excluded from the list of differential diagnosis; nonetheless, if untreated, they can lead to devastating results. Thrombotic thrombocytopenic purpura (TTP) is a thrombotic microangiopathy with characteristic von Willebrand factor (vWF)-rich microthrombi affecting the arterioles and capillaries of multiple organs. It represents both a diagnostic and management challenge to clinicians. Timely recognition and institution of appropriate therapy are of paramount importance in optimizing outcome. Nevertheless, TTP may have an unpredictable behavior once is diagnosed because of its variable frequency of relapses and exacerbations.
Introduction
There are very few hematological emergencies that they are usually excluded from the list of differential diagnosis; nonetheless, if untreated, they can lead to devastating results. Thrombotic thrombocytopenic purpura (TTP) is a thrombotic microangiopathy with characteristic von Willebrand factor (vWF)-rich microthrombi affecting the arterioles and capillaries of multiple organs. It represents both a diagnostic and management challenge to clinicians. Timely recognition and institution of appropriate therapy are of paramount importance in optimizing outcome. Nevertheless, TTP may have an unpredictable behavior once is diagnosed because of its variable frequency of relapses and exacerbations.
Case Report
A 48-year-old African American female presented to the emergency department complaining of right occipital headache and left upper extremity weakness and numbness for 4 days. She also referred left eye pain and slurred speech for 1 day. Her past medical history was remarkable for essential systemic hypertension, diabetes mellitus, and osteoarthritis. She underwent a non-complicated abdominal hysterectomy for uterine fibroids few years before admission. She claimed to be compliant with her home medications that include: amlodipine, benazepril, glimepiride, and occasional non-steroidal antiinflamatory drugs. She denied blurry vision, nausea, vomiting, fever, chills, or confusion. She completed a total of 7-day course of oral ciprofloxacin for a presumptive upper respiratory tract infection, after returning from her native Trinidad & Tobago six months prior to the presenting symptoms.
Her vital signs on admission were: blood pressure of 138/92 mmHg, heart rate of 112 beats/minute, respiratory rate of 19 breaths/minute, and a temperature of 98.4 ºF.
Remarkable findings on physical examination include a decreased muscular strength (3/5) on the left upper extremity. There was no neck rigidity or tenderness to palpation over the temporal areas.
The complete blood count revealed a white blood cell count of 12,300/mm 3 (4. (Fig. 1 ). ADAMTS-13 activity level was <1% (68 -163).
Chest radiography showed no infiltrates. Computed tomography of the head exhibited empty sella turcica without acute infarcts or hemorrhage.
She was admitted to a monitoring bed with the presumptive diagnosis of transient ischemic attack (TIA) or ischemic stroke. Plasma exchange therapy was initiated on day 1 for suspected thrombotic thrombocytopenic purpura (TTP). In addition, corticosteroids (prednisone 40 mg PO daily) were added to the therapy regimen. After the 2nd cycle of plasmapheresis, neurologic symptoms disappeared and deficits resolved, hemoglobin level and platelet count normalized, and lactate dehydrogenase level decreased. She completed a total of 3 cycles of plasmapheresis and was discharged home asymptomatic. She was followed in the Medicine clinic as outpatient after 3 days of discharge from the hospital. She was complaining of generalized weakness. Physical examination was remarkable for jaundice, but no neurologic deficits were found. She was readmitted to the hospital after laboratory results revealed a platelet count of 10,000/mm 3 , a total bilirrubin level of 4.1 mg/dl (0.0 -1.5), a direct bilirrubin level of 3.3 mg/dl (0.0 -0.5), and an LDH level of 1,642 IU/L. Coagulation studies were within normal limits. After 12 hours of admission, she developed cardiac arrest and expired.
Autopsy reported thrombotic thrombocytopenic purpura with congestive heart failure, bilateral pleural effusion, and fatty liver as main causes of death.
Discussion
Thrombotic thrombocytopenic purpura (TTP) is a life-threatening, severe multisystemic disorder of widespread microvascular thrombosis involving the capillaries and arterioles of different organs, characterized by fever, microangiopathic hemolytic anemia, and thrombocytopenia with or without neurological symptoms and impaired renal function [1, 2] .
The pathophysiology of TTP is complex. At autopsy, widespread hyaline thrombi, accompanied by variable fibroblastic infiltration and endothelial overlay, are found in the terminal arterioles and capillaries of multiple organs, most extensively in the heart, brain, kidney, pancreas, spleen, mesentery, and adrenal glands. These thrombi are composed primarily of platelets and von Willebrand factor (vWF) [3, 4] . In addition to serving as the carrier of factor VIII, vWF mediates platelet adhesion and aggregation at sites of vessel injury. Under physiological conditions, the interaction between vWF and platelets is essential for the effective hemostasis at sites of arteriolar or capillary injury. When subjected to shear stress, endothelial vWF polymer is converted to plasma multimers by ADAMTS-13, a zinc metalloprotease that derives primarily from the hepatocytes [2, 5] . By cleaving vWF, ADAMTS-13 mitigates the tendency of vWF and platelets to form agglomerates in normal microcirculation. Thus, the physiological role of ADAMTS-13, the vWF cleaving protease, is to prevent intravascular platelet thrombosis [2] . Under the pathologic conditions of TTP, various intrinsic and extrinsic disorders precipitate ADAMTS-13 deficiency, including genetic mutations, autoimmune inhibitors or autoantibodies against ADAMTS-13, medications (ticlopidine, quinine, clopidogrel), HIV infection, sepsis, malignancy, disseminated intravascular coagulopathy (DIC), liver diseases, pregnancy, acute respiratory distress syndrome (ARDS), and Plasmodium falciparum infection [2, [6] [7] [8] [9] [10] .
Many patients with TTP present with the triad of thrombocytopenia, microangiopathic hemolysis, and neurological abnormalities. Some of them may also have fever and renal abnormalities. However, it is important to note that neither the triad nor the pentad of presentation can be relied upon for the diagnosis of TTP. In practice, a constellation of thrombocytopenia and microangiopathic hemolysis should always raise the suspicion of TTP. Arterial hypertension and acute kidney injury requiring dialysis are uncommon [11] . It is increasingly recognized that patients with TTP may be asymptomatic, but with isolated thrombocytopenia requiring distinction from idiopathic thrombocytopenic purpura (ITP). It may also present with a transient ischemic attack (TIA) or stroke with or without hematological changes [2, 12] . TTP is a potential but infrequent cause of cerebrovascular disease in young adults. Usually, these patients present with headache, irrational behavior, seizures, and focal neurological deficits. Neurological abnormalities are multiple and secondary to microvascular platelet-fibrin thrombi that involve small arteries and capillaries [13] . In a series of 47 patients with acute TTP, the most common neuroradiologic finding was posterior reversible encephalopathy syndrome (PRES), while large ischemic infarctions and hemorrhage were uncommon [14] . During remission, neurocognitive deficits remain highly prevalent, are largely undetected by routine clinical evaluations, and may persist long after recovery from an acute episode of TTP [15, 16] . In the majority of patients with TTP, brain imaging studies do not evidence any abnormalities, as was the case with our patient. Because the diagnostic criteria of TTP are non-specific, the prompt recognition of the disease may be difficult. Differential diagnosis includes disseminated malignant neoplasias, systemic infections, malignant hypertension, systemic lupus erythematosus (SLE), and other thrombotic microangiopathies such as hemolyticuremic syndrome (HUS) [17] [18] [19] . The clinical course of TTP is characterized by recurrent episodes in up to 50% of cases. Neurological symptoms are milder and its prevalence as well as the mortality is significantly lower in recurrences than in the first episode [20] .
In general, thrombotic microangiopathies have been defined as having all the following alterations: microangiopathic hemolytic anemia (hemoglobin < 12 g/dL), negative Coombs test, undetectable serum haptoglobin levels (< 10 mg/dL), more than two fragmented red blood cells (schistocytes) in a 100 × microscopic field, increased LDH levels, thrombocytopenia (< 100,000/mm 3 ), and organic dysfunction (renal and neurological) without signs of DIC [21, 22] . Based on laboratory findings, the differential diagnosis between TTP and other microangiopathies could be challenging. Immediate recognition of TTP is imperative because of the increased mortality, if not treated. Measuring AD-AMTS-13 activity levels may not guarantee initial diagnosis and therapeutic decisions, but it is important for the prognosis. An ADAMTS-13 activity level < 5% -10% seems to have increased specificity for TTP, but it does not identify all patients at risk for relapsing. ADAMTS-13 activity levels of > 10% makes the diagnosis of TTP unlikely in patients presenting with acute thrombocytopenia [2, 23, 24] .
Therapeutic plasma exchange is the main therapy for patients with TTP [25] . Plasma exchange delivers elevated ADAMTS-13 dose without circulatory overload and removes antibodies to ADAMTS-13, recovering ADAMTS-13 activity. The treatment approach consists of a 1 to 1.5 plasma volume exchange with plasma daily until clinical symptoms have resolved and the platelet count has reached a normal level [24] . LDH levels should also be monitored since it reflects ongoing tissue ischemia as well as hemolysis [26] . Schistocytes measurements are not predictive of ability to maintain remission after cessation of therapy [27] . During remission of TTP, measurements of ADAMTS-13 levels may also be helpful. ADAMTS-13 activity levels < 5% -10% are associated with high risk of relapse in the near future [28] . Although few schistocytes were found on the follow up peripheral blood smear, the patient discussed in this report demonstrated resolution of neurological deficits and normalization of the platelet count after the 2nd cycle of plasma exchange therapy. This patient did not have a follow up ADAMTS-13 activity level. In recurrences of TTP, platelet count is usually higher and the LDH levels lower than the first episode of the disease [20] . On readmission, our patient presented with more severe thrombocytopenia and higher LDH levels. There is evidence that the plasma exchange therapy would have only a transient effect on the presumably autoimmune basis of the disease, and that additional immunosuppressive therapy could lead to a longer-lasting response [29] . Treatment with immunosuppressive agents is reserved for patients suspected of having ADAMTS-13 autoimmune deficiency. Glucocorticoids are the immunosuppressive agents initially administered. Other agents such as rituximab and cyclosporine are used for more critically-ill patients and patients with recurrent disease [30, 31] . Aspirin is not used as adjuvant treatment, but is appropriate for patients with baseline cardiac or neurologic dysfunction and without severe thrombocytopenia. Other therapies used with variable success include cyclophosphamide, vincristine, azathioprine, intravenous immunoglobulins, and splenectomy. Despite the institution of appropriate treatment, mortality among patients with TTP remains approximately 15%. However, 50% of the deaths can be attributed to treatment-related complications [32] . Even after recognizing and treating the disease, patients have a significantly altered quality of life, with progressive memory loss and fatigue [33] .
At the present time, the main clinical value of AD-AMTS-13 activity assay is as a marker for outcome and the potential for relapse. Patients with severe deficiency of AD-AMTS-13 experience higher rates of remission and lower mortality [34] .
Rapid diagnosis and treatment are necessary for decreasing the risk of fatal outcome in patients with TTP. Clinicians should be familiar with the clinical presentation and laboratory abnormalities of TTP, in order to make early diagnosis and initiate appropriate therapy.
